BioCentury
ARTICLE | Distillery Therapeutics

Cancer

October 10, 2017 8:42 PM UTC

Patient sample, cell culture, mouse and monkey studies suggest ERY974, a bispecific antibody against CD3 and GPC3, could help treat multiple types of GPC3-positive solid tumors. In tissue samples from patients with adenocarcinoma, esophageal carcinoma, gastric cancer, head and neck cancer, hepatocellular carcinoma (HCC) and lung carcinomas, GPC3 expression was higher in tumors than in the corresponding normal tissues from the patients. In co-culture of a human GPC3-positive liver adenocarcinoma cell line and human peripheral blood monocytes (PBMCs), the anti-CD3/GPC3 antibody ERY974 induced T cell-dependent cellular cytotoxicity and increased expression of T cell activation markers compared with a control antibody, whereas in co-culture of a human GPC3-negative liver adenocarcinoma cell line and PBMCs, ERY974 had no effect. In multiple xenograft mouse models of GPC3-positive esophageal, gastric, HCC, head and neck, lung and ovarian cancers, ERY974 increased infiltration of T cells and granulocytes into tumors and decreased tumor growth compared with no treatment. In cynomolgus monkeys, high doses of ERY974 caused no observable cytotoxicity or organ toxicities. Next steps by Chugai Pharmaceutical Co. Ltd. include identifying optimum combinations of ERY974 with various other anticancer agents...

BCIQ Company Profiles

Chugai Pharmaceutical Co. Ltd.

BCIQ Target Profiles

Glypican 3 (GPC3)